

CURRICULUM VITAE EUROPEO



INFORMAZIONI PERSONALI

NOME	FEDERICA MORANO
E-MAIL	federica.morano@istitutotumori.mi.it
NAZIONALITA'	Italiana
DATA DI NASCITA	13/04/1985

ESPERIENZE LAVORATIVE

AGOSTO 2021 – ALLA DATA ODIERNA :

DIRIGENTE MEDICO A TEMPO INDETERMINATO PRESSO FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO

MAGGIO 2019 – LUGLIO 2021 :

DIRIGENTE MEDICO A TEMPO DETERMINATO PRESSO FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO

AGOSTO 2015 – MAGGIO 2019:

ONCOLOGO MEDICO PRESSO FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO

AGOSTO 2014 – GIUGNO 2015:

HONORARY RESEARCH FELLOW PRESSO LA GI & LYMPHOMA UNIT, THE ROYAL MARSDEN NHS FOUNDATION TRUST, SUTTON, SURREY, REGNO UNITO

MAGGIO 2010 – GIUGNO 2015:

MEDICO IN FORMAZIONE SPECIALISTICA PRESSO LA "SAPIENZA" UNIVERSITÀ DI ROMA.

LUGLIO 2009 - MAGGIO 2010:

MEDICO FREQUENTATORE PRESSO IL DAY-HOSPITAL ONCOLOGICO DEL POLICLINICO UMBERTO I, "SAPIENZA" UNIVERSITÀ DI ROMA

DICEMBRE 2007 – LUGLIO 2009:

STUDENTE FREQUENTATORE PRESSO IL DAY-HOSPITAL ONCOLOGICO DEL POLICLINICO UMBERTO I, "SAPIENZA" UNIVERSITÀ DI ROMA

EDUCAZIONE

09/06/2015: SPECIALIZZAZIONE IN ONCOLOGIA MEDICA PRESSO LA
"SAPIENZA" UNIVERSITA' DI ROMA
VOTO FINALE: 70/70 SUMMA CUM LAUDE

03/03/2010: ISCRIZIONE ALL' "ALBO DEI MEDICI - CHIRURGHI" DI MATERA

27/07/2009: LAUREA IN MEDICINA E CHIRURGIA PRESSO LA "SAPIENZA"
UNIVERSITA' DI ROMA
VOTO FINALE: 110/110 SUMMA CUM LAUDE

LUGLIO 2003: DIPLOMA DI SCUOLA SUPERIORE PRESSO IL LICEO
SCIENTIFICO "ENRICO FERMI", POLICORO (MATERA)
VOTO FINALE : 100/100

LINGUA MADRE

ITALIANO

ALTRE LINGUE PARLATE

INGLESE

PREMI E RICONOSCIMENTI

25/10/2018: 4° POSTO PREMIO MARZIA GALLI KLENLE

16/11/2018: MIGLIOR PRESENTAZIONE ORALE AL XX CONGRESSO
NAZIONALE AIOM

"MICROSATELLITE INSTABILITY (MSI) IN RESECTED GASTRIC CANCER:
CORRELATION WITH CLINICOPATHOLOGIC AND MOLECULAR PROFILE. A
TRANSLATIONAL ANALYSIS OF ITACA-S STUDY"

31/12/2020: PREMIO GIOVANI RICERCATORI 2019-2020 – AREA RICERCA
CLINICA – FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO

INFORMAZIONI AGGIUNTIVE

MEMBRO DELL' "ASSOCIAZIONE ITALIANA ONCOLOGIA MEDICA" (AIOM)
MEMBRO DELL' "EUROPEAN SOCIETY OF MEDICAL ONCOLOGY" (ESMO)
MEMBRO DEL "GRUPPO ONCOLOGICO NORD-OVEST" (GONO)

ALLEGATO

PUBBLICAZIONI

PUBBLICAZIONI

1. Mezi S, Musio D, Orsi E, de Felice F, Verdinelli I, **Morano F**, Raffetto N, Tombolini V. Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. *Acta Oncol.* 2013 Jan;52(1):187-90. doi: 10.3109/0284186X.2012.689114. Epub 2012 Jun 7.
2. Passaro A, Palazzo A, Trenta P, Mancini ML, **Morano F**, Cortesi E. Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. *Curr Med Chem.* 2012;19(22):3689-700. Review.
3. Iacovelli R, Palazzo A, Mezi S, **Morano F**, Naso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. *Acta Oncol.* 2012 Sep;51(7):873-9. doi: 10.3109/0284186X.2012.705019
4. Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. (COLLABORATORS: Cognetti F, Rosso R, Venturini M, De Placido S, Bruzzi P, Pastorino S, Venturini M, Abate A, Pastorino S, Canavese G, Vecchio C, Guenzi M, Lambertini M, Levaggi A, Giraudi S, Accortanzo V, Floris C, Aitini E, Fornari G, Miraglia S, Buonfanti G, Cherchi M, Petrelli F, Vaccaro A, Magnolfi E, Contu A, Labianca R, Parisi A, Basurto C, Cappuzzo F, Merlano M, Russo S, Mansutti M, Poletto E, Nardi M, Grasso D, Fontana A, Isa L, Comandè M, Cavanna L, Iacobelli S, Milani S, Mustacchi G, Venturini S, Scinto A, Sarobba M, Pugliese P, Bernardo A, Pavese I, Cocco M, Massidda B, Ionta MT, Nuzzo A, Laudadio L, Chiantera V, Dottori R, Barduagni M, Castiglione F, Ciardiello F, Tinessa V, Ficorella A, Moschetti L, Vallini I, Giardina G, Silva R, Montedoro M, Seles E, **Morano F**, Cruciani G, Adamo V, Pancotti A, Palmisani V, Ruggeri A, Cammilluzzi E, Carrozza F, D'Aprile M, Brunetti M, Gallotti P, Chiesa E, Testore F, D'Arco A, Ferro A, Jirillo A, Pezzoli M, Scambia G, Iacono C, Masullo P, Tomasello G, Gandini G, Zoboli A, Bottero C, Cazzaniga M, Genua G, Palazzo S, D'Amico M, Perrone D). Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. *Lancet.* 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2.
5. Grande R, Natoli C, Ciancola F, Gemma D, Pellegrino A, Pavese I, Garufi C, Di Lauro L, Corsi D, Signorelli D, Sperduti I, Cortese G, Risi E, **Morano F**, Sergi D, Signorelli C, Ruggeri EM, Zampa G, Russano M, Gamucci T. Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. *PLoS One.* 2016 Jul 21;11(7):e0157751. doi: 10.1371/journal.pone.0157751.
6. Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, **Morano F**, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, Di Nicolantonio F. MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer. *Cancer Discov.* 2016 Sep;6(9):963-71. doi: 10.1158/2159-8290.CD-16-0297.
7. Pietrantonio F, Perrone F, Mennitto A, Gleeson EM, Milione M, Tamborini E, Busico A, Settanni G, Berenato R, Caporale M, **Morano F**, Bossi I, Pellegrinelli A, Di Bartolomeo M, de Braud F, Baratti D,

- Bowne WB, Kusamura S, Deraco M. Towards the molecular dissection of peritoneal pseudomyxoma. *Ann Oncol*. 2016 Nov;27(11):2097-2103.
8. Pietrantonio F, Caporale M, **Morano F**, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *nt J Cancer*. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408.
 9. Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, Gloghini A, Tamborini E, Lonardi S, **Morano F**, Picciani B, Busico A, Volpi CC, Martinetti A, Battaglin F, Bossi I, Pellegrinelli A, Milione M, Cremolini C, Di Bartolomeo M, Bardelli A, de Braud F. Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. *Clin Cancer Res*. 2016 Oct 25. doi: 10.1158/1078-0432.CCR-16-1863
 10. Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, **Morano F**, Rossini D, Battaglin F, Baretta M, Berenato R, Formica V, Mosconi S, Petrelli F, Ghidini M, Loupakis F, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C. Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. *Ann Oncol*. 2017 Mar 1;28(3):555-561. doi: 10.1093/annonc/mdw627.
 11. Pietrantonio F, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, **Morano F**, Coppa J, Perrone F, Iacovelli R, Milione M, Alessi A, Vaiani M, Bossi I, Ricchini F, Scotti M, Caporale M, Bajetta E, de Braud F, Mazzaferro V. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. *Clin Colorectal Cancer*. 2016 Oct 6. pii: S1533-0028(16)30201-8. doi: 10.1016/j.clcc.2016.09.007.
 12. Scalfani F, **Morano F**, Cunningham D, Baratelli C, Kalaitzaki E, Watkins D, Starling N, Chau I, Rao S. Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. *Oncologist*. 2017 Apr;22(4):402-408. doi: 10.1634/theoncologist.2016-0241. Epub 2017 Feb 16.
 13. Scalfani F, Brown G, Cunningham D, Rao S, Tekkis P, Tait D, **Morano F**, Baratelli C, Kalaitzaki E, Rasheed S, Watkins D, Starling N, Wotherspoon A, Chau I. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. *Oncologist*. 2017 May 5. pii: theoncologist.2016-0396. doi: 10.1634/theoncologist.2016-0396. [Epub ahead of print]
 14. Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, **Morano F**, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, Di Nicolantonio F. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. *Br J Cancer*. 2017 Jul 25;117(3):347-352. doi: 10.1038/bjc.2017.196. Epub 2017 Jun 27.
 15. Raspagliesi F, Bogani G, Ditto A, Martinelli F, Chiappa V, Borghi C, Scaffa C, **Morano F**, Maltese G, Lorusso D. Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers. *Ann Surg Oncol*. 2017 Oct;24(11):3396-3405. doi: 10.1245/s10434-017-6030-0. Epub 2017 Aug 9.

16. Berenato R, **Morano F**, Pietrantonio F, Cotsoglou C, Caporale M, Infante G, Pellegrinelli A, Alessi A, Battiston C, Coppa J, Padovano B, Mennitto A, Niger M, Fucà G, Lazzati S, Greco G, Delconte G, de Braud F, Mazzaferro V, Di Bartolomeo M. Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. *Oncology*. 2017 Sep 8. doi: 10.1159/000479154. [Epub ahead of print]
17. Cremolini C, **Morano F**, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, Pietrantonio F. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. *Ann Oncol*. 2017 Sep 25. doi: 10.1093/annonc/mdx546. [Epub ahead of print]
18. Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, **Morano F**, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. *Nature*. 2017 Nov 29. doi: 10.1038/nature24673. [Epub ahead of print]
19. Nichetti F, **Morano F**, Fabbri A, de Braud F, Di Bartolomeo M. Bilateral parotid gland metastases from gastric signet-ring cell carcinoma. *Tumori*. 2017 Nov 22:0. doi: 10.5301/tj.5000690. [Epub ahead of print]
20. Pietrantonio F, Fucà G, **Morano F**, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, De Braud FG, Giordano S, Cremolini C, Di Bartolomeo M. Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study. *Clin Cancer Res*. 2017 Dec 5. pii: clincanres.2781.2017. doi: 10.1158/1078-0432.CCR-17-2781. [Epub ahead of print]
21. Cremolini C, Pietrantonio F, Tomasello G, Dadduzio V, Moretto R, **Morano F**, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, Nichetti F, Ziampiri S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, De Braud F, Loupakis F, Lonardi S. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. *ESMO Open*. 2017 Aug 10;2(3):e000241. doi: 10.1136/esmoopen-2017-000241. eCollection 2017.
22. Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, **Morano F**, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. *J Natl Cancer Inst*. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.
23. Battaglin F, Schirripa M, Buggin F, Pietrantonio F, **Morano F**, Boscolo G, Tonini G, Lutrino ES, Lucchetti J, Salvatore L, Passardi A, Cremolini C, Arnoldi E, Scartozzi M, Pella N, Boni L, Bergamo F, Zagonel V, Loupakis F, Lonardi S. The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. *BMC Cancer*. 2018 Jan 25;18(1):98. doi: 10.1186/s12885-018-4001-x.

24. Cremolini C, Milione M, Marmorino F, **Morano F**, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. *Br J Cancer*. 2018 Mar 13. doi: 10.1038/s41416-018-0015-z. [Epub ahead of print]
25. Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, **Morano F**, Fucà G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa S, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. *Ann Oncol*. 2018 Mar 10. doi: 10.1093/annonc/mdy090. [Epub ahead of print]
26. Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, **Morano F**, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. *Target Oncol*. 2018 Mar 27. doi: 10.1007/s11523-018-0562-5. [Epub ahead of print]
27. **Morano F**, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. *Ann Oncol*. 2018 May 31. doi: 10.1093/annonc/mdy197. [Epub ahead of print]
28. Kühnl A, Cunningham D, Hutka M, Peckitt C, Rozati H, **Morano F**, Chong I, Gillbanks A, Wotherspoon A, Harris M, Murray T, Chau I. Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients. *BMC Hematol*. 2018 Aug 14;18:19. doi: 10.1186/s12878-018-0109-0. eCollection 2018
29. Pietrantonio F, Barretta F, Fanotto V, Park SH, **Morano F**, Fucà G, Niger M, Prisciandaro M, Silvestris N, Bergamo F, Fornaro L, Bordonaro R, Rimassa L, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Leone F, Faloppi L, Di Donato S, de Braud F, Lee J, De Vita F, Di Bartolomeo M, Miceli R, Aprile G. Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. *Oncology*. 2018 Aug 21:1-9. doi: 10.1159/000491753. [Epub ahead of print]
30. **Morano F**, Sclafani F. Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice. *Crit Rev Oncol Hematol*. 2018 Nov;131:53-65. doi: 10.1016/j.critrevonc.2018.08.006. Epub 2018 Aug 27.
31. Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, **Morano F**, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V. Perioperative bevacizumab-based triplet chemotherapy in patients with potentially resectable colorectal cancer liver metastases. *Clin Colorectal Cancer*. 2018 Nov 24. pii: S1533-0028(18)30212-3

32. Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari M A, Di Bartolomeo M, **Morano F**, Raimondi A, Fuca` G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Carlo Barone, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA methyltransferase. *European Journal of Cancer* 107 (2019) 164e174
33. Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, **Morano F**, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F. Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. *Sci Rep.* 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3.
34. Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, **Morano F**, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, Pietrantonio F. Benefit from anti-EGFRs in *RAS* and *BRAF* wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. *ESMO Open* 2019;4:e000489. doi:10.1136/esmoopen-2019-000489
35. Moretto R, **Morano F**, Ongaro E, Rossini D, Pietrantonio F, Casagrande M, Antoniotti C, Corallo S, Marmorino F, Cortiula F, Nichetti F, Borelli B, Zucchelli G, Boccaccino A, Masi G, De Braud F, Falcone A, Cremolini C. Lack of benefit from anti-EGFR treatment in *RAS* and *BRAF* wildtype metastatic colorectal cancer with mucinous histology or mucinous component. *Clinical Colorectal Cancer* (2019), doi: <https://doi.org/10.1016/j.clcc.2019.02.007>.
36. Di Bartolomeo M, Monica Niger M, **Morano F**, Corallo S, Antista M, Tambari S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassinetti GL, Tassinari D, Giulian F, Cinieri S, Maiello E, Verusio C, Sergio Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Soto Parra H, Fornaro L, Caporale M, de Braud F, Pietrantonio F. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. *BMC Cancer* (2019) 19:283 <https://doi.org/10.1186/s12885-019-5498-3>
37. Raimondi A, Corallo S, Niger M, Antista M, Randon G, **Morano F**, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F. Metronomic capecitabine plus cyclophosphamide regimen in unresectable or relapsed Pseudomyxoma Peritonei. *Clinical Colorectal Cancer* (2019). Doi: <https://doi.org/10.1016/j.clcc.2019.03.002>
38. Miceli R, An J, Di Bartolomeo M, **Morano F**, Kim ST, Park SH, Choi MG, Lee JH, Raimondi A, Fucà G, Sohn TS, Bae JM, Kim S, Lim DH, Kang WK, Kim KM, Pietrantonio F, Lee J. Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. *Oncology* (2019) May 2:1-6. doi: 10.1159/000499628. [Epub ahead of print]
39. Pietrantonio F, **Morano F**, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smirardo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F. Maintenance

Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncol.* 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print]

40. Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Ceglie MA, Siena S, **Morano F**, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M. A validated prognostic classifier for ^{V600E}BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. *Volume 118*, September 2019, Pages 121-130
41. Salati M, Orsi G, Smyth E, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, **Morano F**, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S. Gastric cancer: Translating novel concepts into clinical practice. *Cancer Treat Rev.* 2019 Aug 14;79:101889. doi: 10.1016/j.ctrv.2019.101889. [Epub ahead of print]
42. Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, **Morano F**, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Ruggie M, Zagonel V, Di Maio M, Fassan M. CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. *Br J Cancer.* 2019 Sep 2. doi: 10.1038/s41416-019-0560-0. [Epub ahead of print]
43. Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, **Morano F**, Wotherspoon A, Valeri N, Kook MC, An JY, Grabsch HI, Fucà G, Noh SH, Sohn TS, Kim S, Di Bartolomeo M, Cunningham D, Lee J, Cheong JH, Smyth EC. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. *J Clin Oncol.* 2019 Sep 12;JCO1901124. doi: 10.1200/JCO.19.01124. [Epub ahead of print]
44. **Morano F**, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. *J Clin Oncol.* 2019 Sep 20;JCO1901254. doi: 10.1200/JCO.19.01254. [Epub ahead of print]
45. Corso S, Isella C, Bellomo SE, Apicella M, Durando S, Migliore C, Ughetto S, D'Errico L, Menegon S, Moya-Rull D, Cargnelutti M, Capeloa T, Conticelli D, Giordano J, Venesio T, Balsamo A, Marchiò C, Degiuli M, Reddavid R, Fumagalli Romario U, de Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molino S, Pietrantonio F, **Morano F**, Siena S, Sartore-Bianchi A, Bencivenga M, Mengardo V, Rosati R, Marrelli D, Morgagni P, Rausei S, Pallabazzer G, De Simone M, Ribero D, Marsoni S, Sottile A, Medico E, Cassoni P, Sapino A, Pectasides E, Thorner AR, Nag A, Drinan SD, Wollison BM, Bass AJ, Giordano S. A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. *Cancer Res.* 2019 Oct 4. pii: canres.1166.2019. doi: 10.1158/0008-5472.CAN-19-1166. [Epub ahead of print]
46. Crisafulli G, Mssolin B, Cassingena A, Montone M, Bartolini A, Barault L, Martinetti A, **Morano F**, Pietrantonio F, Sartore-Bianchi A, Siena S, Di Nicolantonio F, Marsoni S, Bardelli A, Siravegna G.

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patient. ESMO Open 2019;4:e000572. doi: 10.1136/esmoopen-2019-000572

47. Pietrantonio F, Lobefaro R, Antista M, Lonardi S, Raimondi A, **Morano F**, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, Petrelli F, Gori S, Randon G, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fucà G, Di Bartolomeo M and de Braud F. Capecitabine and temozolomide versus FOLFIRI in *RAS* mutated, *MGMT* methylated metastatic colorectal cancer. Clin Cancer Res November 18 2019 DOI: 10.1158/1078-0432.CCR-19-3024
48. Di Bartolomeo M, **Morano F**, Raimondi A, Miceli R, Corallo S, Tamborini E, Perrone F, Antista M, Niger M, Pellegrinelli A, Randon G, Pagani F, Martinetti A, Fucà G, Pietrantonio F; ITACA-S study group. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Oncologist. 2019 Nov 25. pii: theoncologist.2019-0471. doi: 10.1634/theoncologist.2019-0471. [Epub ahead of print]
49. Giannini R, Zucchelli G, Giordano M, Ugolini C, Moretto R, Ambryszewska K, Leonardi M, Sensi E, **Morano F**, Pietrantonio F, Cremolini C, Falcone A, Fontanini G. Immune Profiling of Deficient Mismatch Repair Colorectal Cancer (dMMR CRC) Tumor Microenvironment Reveals Different Levels of Immune System Activation. J Mol Diagn 2020 Mar 12[Online ahead of print].doi: 10.1016/j.jmoldx.2020.02.008
50. Corallo S, Fucà G, **Morano F**, Salati M, Spallanzani A, Gloghini A, Volpi CC, Trupia DV, Lobefaro R, Guarini V, Milione M, Cattaneo L, Antista M, Prisciandaro M, Raimondi A, Sposito C, Mazzaferro V, de Braud F, Pietrantonio F, Di Bartolomeo M. Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. Oncologist 2020 Apr 9. doi: 10.1634/theoncologist.2020-0037.
51. Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, **Morano F**, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist 2020 May 5. doi: 10.1634/theoncologist.2020-0014.
52. Fucà G, Guarini V, Antoniotti C, **Morano F**, Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L, Sartore-Bianchi A, Borelli B, Tampellini M, Bustreo S, Claravazza M, Boccaccino A, Murialdo R, Zaniboni A, Tomasello G, Loupakis F, Adamo V, Tonini G, Cortesi E, de Braud F, Cremolini C, Pietrantonio F. The Pan-Immune-Inflammation Value Is a New Prognostic Biomarker in Metastatic Colorectal Cancer: Results From a Pooled-Analysis of the Valentino and TRIBE First-Line Trials. Br J Cancer 2020 May 19. doi: 10.1038/s41416-020-0894-7. Online ahead of print.
53. Pietrantonio F, **Morano F**, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clin Colorectal Cancer. 2020 May 23;S1533-0028(20)30077-3. doi: 10.1016/j.clcc.2020.05.004.

54. Moretto R, Corallo S, Belfiore A, Rossini D, Boccaccino A, Lonardi S, Centonze G, **Morano F**, Germani MM, Loupakis F, Morelli L, Urbani L, Brich S, Marmorino F, Prisciandaro M, Aprile G, Fassan M, Cillo U, Cattaneo L, Fontanini G, De Braud F, Falcone A, Milione M, Pietrantonio F, Cremolini C. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. *Eur J Cancer*. 2020 Jun 15;135:78-88. doi: 10.1016/j.ejca.2020.04.045. Online ahead of print.
55. Raimondi A, Di Maio M, **Morano F**, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Sartore-Bianchi A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Adamo V, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Bergamo F, Niger M, Antista M, Peverelli G, de Braud F, Di Bartolomeo M, Pietrantonio F. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. *Eur J Cancer* 2020 Aug;135:230-239. doi: 10.1016/j.ejca.2020.04.048. Epub 2020 Jul 2.
56. Antoniotti C, Borelli B, Rossini D, Pietrantonio F, **Morano F**, Salvatore L, Lonardi S, Marmorino F, Tamberi S, Corallo S, Tortora G, Bergamo F, Brunella DS, Boccaccino A, Grassi E, Racca P, Tamburini E, Aprile G, Moretto R, Boni L, Falcone A, Cremolini C. Atezotribe: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. *BMC Cancer* . 2020 Jul 22;20(1):683. doi: 10.1186/s12885-020-07169-6.
57. Manca P, Corallo S, Randon G, Lonardi S, Cremolini C, Rimassa L, Bergamo F, Antoniotti C, Smirardo V, Zaniboni A, Murialdo R, Tampellini M, Tomasello G, Clavarezza M, Racca P, Antista M, Raimondi A, Prisciandaro M, Pagani F, Palermo F, Greco FG, Vaiani M, Di Bartolomeo M, de Braud F, Calareso G, **Morano F**, Pietrantonio F. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. *Eur J Cancer*. 2020 Dec 12;144:31-40. doi: 10.1016/j.ejca.2020.11.017. Online ahead of print.
58. Pietrantonio F, Fucà G, Rossini D, Schmoll HJ, Bendell JC, **Morano F**, Antoniotti C, Corallo S, Borelli B, Raimondi A, Marmorino F, Niger M, Boccaccino A, Masi G, Lonardi S, Boni L, de Braud F, Di Bartolomeo M, Falcone A, Cremolini C. FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer patients: a propensity score-based analysis. *Oncologist*. 2020 Dec 18. doi: 10.1002/onco.13642. Online ahead of print.
59. Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, Randon G, de Braud F, Di Bartolomeo M, Pietrantonio F, **Morano F**. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. *Support Care Cancer* 2021 Jan 3. doi: 10.1007/s00520-020-05972-2. Online ahead of print.
60. Corso S, Pietrantonio F, Apicella M, Migliore C, Conticelli D, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Ughetto S, Degiuli M, Reddavid R, Fumagalli Romario U, de Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molino S, de Manzoni G, Bencivenga M, Siena S, Sartore-Bianchi A, **Morano F**, Corallo S, Prisciandaro M, Di Bartolomeo M, Gloghini A, Marsoni S, Sottile A, Sapino A, Marchiò C, Dahle-Smith A, Miedzybrodzka Z, Lee J, Ali SM, Ross JS, Alexander BM, Miller VA, Petty R, Schrock AB, Giordano S. Optimized EGFR blockade strategies in EGFR addicted gastroesophageal

adenocarcinomas. Clin Cancer Res.2021 Feb 4;clincanres.0121.2020. doi: 10.1158/1078-0432.CCR-20-0121. Online ahead of print.

61. Manca P, Corallo S, Busico A, Lonardi S, Corti F, Antoniotti C, Procaccio L, Clavarezza M, Smirolto V, Tomasello G, Murialdo R, Sartore-Bianchi A, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Palermo F, Perrone F, Tamborini E, Prisciandaro M, Raimondi A, Di Bartolomeo M, **Morano F**, Pietrantonio F. The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer. Clin Cancer Res. 2021 Feb 5;clincanres.4699.2020. doi: 10.1158/1078-0432.CCR-20-4699. Online ahead of print.
62. Fassan M, Milione M, Maddalena G, Cremolini C, Schirripa M, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Bergamo F, Volante M, Boccaccino A, **Morano F**, Cortiula F, De Maglio G, Rimassa L, Smirolto V, Calveti L, Aprile G, Salvatore L, Santini D, Salmaso R, Centonze G, Bion P, Borga C, Lonardi S, Zagonel V, Dei Tos AP, Di Maio M, Loupakakis F. Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. Eur J Cancer. 2021 Mar;146:145-154. doi: 10.1016/j.ejca.2021.01.016. Epub 2021 Feb 16.
63. Borelli B, Fontana E, Giordano M, Antoniotti C, Lonardi S, Bergamo F, Pietrantonio F, **Morano F**, Tamburini E, Boccaccino A, Santini D, Zucchelli G, Pella N, Maiello E, Passardi A, Zaniboni A, Ugolini C, Fontanini G, Falcone A, Nyamundanda G, Sadanandam A, Cremolini C. Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. ESMO Open. 2021 Mar 3;6(2):100073. doi: 10.1016/j.esmoop.2021.100073. Online ahead of print.
64. Ughetto S, Migliore C, Pietrantonio F, Apicella M, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Rizzolio S, Capelôa T, Ribisi S, Degiuli M, Reddavid R, Rapa I, Fumagalli U, De Pascale S, Ribero D, Baronchelli C, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Manenti S, Bencivenga M, Sacco M, Castelli C, Siena S, Sartore-Bianchi A, Tosi F, **Morano F**, Raimondi A, Prisciandaro M, Gloghini A, Marsoni S, Sottile A, Sarotto I, Sapino A, Marchiò C, Cassoni P, Guarrera S, Corso S, Giordano S. Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric Cancer. 2021 Mar 23. doi: 10.1007/s10120-021-01165-w. Online ahead of print. PMID: 33755862
65. Fucà G, Corti F, Ambrosini M, Intini R, Salati M, Fenocchio E, Manca P, Manai C, Daniel F, Raimondi A, **Morano F**, Corallo S, Prisciandaro M, Spallanzani A, Quarà V, Belli C, Vaiani M, Curigliano G, Cremolini C, De Braud F, Di Bartolomeo M, Zagonel V, Lonardi S, Pietrantonio F. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer . 2021 Apr;9(4):e002501. doi: 10.1136/jitc-2021-002501.
66. Randon G, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, Pagani F, Germani MM, Ambrosini M, Rossini D, Ratti M, Salvà F, Richman SD, Wood H, Nanjangud G, Gloghini A, Milione M, Bardelli A, de Braud F, **Morano F**, Cremolini C, Pietrantonio F. EGFR Amplification in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2021 Apr 7:djab069. doi: 10.1093/jnci/djab069. Online ahead of print. PMID: 33825902
67. Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C, Borelli B, Brambilla M, Prete AA, Quarà V, Antista M, Fassan M, **Morano F**, Spallanzani A, Ambrosini M, Curigliano G, de Braud F, Zagonel V, Fucà G, Pietrantonio F. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021 Jun;150:155-167. doi: 10.1016/j.ejca.2021.03.043. Epub 2021 Apr 24.

La sottoscritta è a conoscenza che, ai sensi dell'art.76 DPR 28/12/2000 n.445, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, la sottoscritta autorizza al trattamento dei dati personali, secondo quanto previsto dal D. lgs. 196/03.

Milano 2/08/2021

A handwritten signature in black ink, appearing to read "Federica Morano". The signature is fluid and cursive, with the first name "Federica" written in a larger, more prominent script than the last name "Morano".